Press Releases

American Biogenetic Sciences Diagnostic Test May Prove to be Novel Marker for Life Threatening Complication of Pregnancy

Condition Known As Preeclampsia Complicates Up To 10% of Pregnancies

Miami Beach, FL, February 3, 2000 - A report presented at the Society for Maternal and Fetal Medicines Annual Meeting indicates that American Biogenetic Sciences, Inc. (ABS) (OTCBB:MABA) patented FDA approved diagnostic test, Thrombus Precursor Protein (TpPTM) may offer doctors a new tool in the early diagnosis of a life threatening complication of pregnancy called preeclampsia. Researchers at the Department of Obstetrics and Gynecology, at New York University (NYU) School of Medicine found that women destined to develop preeclampsia have lower levels of TpP in the second trimester of pregnancy, prior to the onset of clinical manifestations of the disease.

The researchers lead by Dr. Michael Paidas, Director of the NYU Program for Maternal and Fetal Medicine and others, concluded that while the second trimester of pregnancy is associated with increased thrombin activity (increased risk of blood clotting) patients that go on to have preeclampsia demonstrate lower thrombin activity. While the underlying cause of preeclampsia is not known, the phenomenon is thought to be a function of impaired uteroplacental vascular remodeling. Because of the exquisite sensitivity of the TpP marker to soluble fibrin polymer, it may provide valuable diagnostic and prognostic information early in this dangerous condition.

“We are extremely excited about the healthcare implications of being able to diagnose this dangerous condition prior to the onset of clinical manifestations of the disease,” said John S. North, President and CEO of ABS. While these results are preliminary and further clinical trials need to be done, I can foresee a time when TpP testing, a simple blood analysis, could become a valuable addition to a panel of standard tests for the millions of women who become pregnant each year.”

The condition preeclampsia (also known as toxemia) happens in nearly 10% of all pregnancies and is characterized by dangerously high blood pressure, and generalized edema, and protein in the urine. Preeclampsia can prevent the placenta from getting enough blood, depriving the unborn baby of oxygen and nutrients. In severe cases mothers may experience seizures which have very serious consequences for the mother and baby. A doctors ability to diagnose this condition at an early stage will allow expecting mothers to get appropriate treatment and reduce the risk to both the mother and unborn child.

American Biogenetic Sciences, based in Copiague, New York, researches and develops diagnostic tests for cardiac conditions and infectious diseases, as well as new treatments for neurological disorders including epilepsy, migraine, mania, Parkinson's and Alzheimer's disease. ABS also seeks out new technologies and conducts research and development through its Global Scientific Network in the U.S., Europe, Israel, Russia and China.

Statements in this release that are not strictly historical are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For further details and a discussion of these risks and uncertainties, see the Company's Securities and Exchange Commission filings, including its annual report or Form 10-K.